Harrow (HROW) said Thursday that a California jury ruled in favor of its subsidiary ImprimisRx in a trademark infringement against OSRX and Ocular Science.
The jury awarded $34.9 million in damages, which included $20.4 million in punitive damages and $14.5 million is actual damages, Harrow said.
OSRX did not immediately respond to a request by MT Newswires for comment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.